Thursday, January 27, 2022
Avivagen Inc. (VIVXF)(VIV:CA)
Names A President, Reports Fiscal 2021 Results
Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
4Q21 Results. Avivagen’s management reported revenue of $368,504 (all figures in Canadian $) in the quarter, up from $287,897 last year, but down from our estimated revenue of $1.4 million. The miss is mostly due to a Philippines order that will be recognized in the first quarter of fiscal 2022. Net loss for the quarter was $1.4 million, or $0.03 per share versus a net loss of $1.2 million, or $0.03 per share, in 4Q20. We had forecasted a net loss of $993,00, or $0.02 per share.
FY21 Results. Revenue for the 2021 fiscal year was reported at $1.3 million, a $0.1 million increase over the prior year’s $1.2 million. Operating loss for the year totaled $4.1 million compared to a loss of $3.4 million in fiscal 2020, due to an increase in finance cost and increasing operational expenses. Net loss was reported at $6.4 million or $0.12 per share, versus a $4.8 million loss, or …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
